The way I express it to registrants, to any user sector, to the health groups, and to the environmental groups is that we are trying to minimize the costs the Canadian regulatory system brings to bear on registrants. We are also trying to have incentives to get products registered, so the registrants get a shorter timeline for the joint reviews. We agreed last year at NAFTA to a 25% decrease in efficacy trials, which is a savings in the hundreds of thousands of dollars, as an incentive for them to come to both Canada and the United States at the same time, so our farmers have access to the same product at the same time.
As I said, our new proposal on protecting intellectual property is that for every three minor uses they put on the label they'll get a year. The proposal is added protection as an incentive for them adding more minor uses, and for the first time in PMRA, with this project we've dedicated our own resources to addressing the technology gap. We are working to address that.